In focus · trending topic

partial onset seizures

8 stories · following the connections

Adamas Reports First Quarter 2018 Financial Results

By Nasdaq OMXMay 3, 2018, 8:06 PM UTC

Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

By Nasdaq OMXSep 7, 2017, 12:30 PM UTC

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

By Nasdaq OMXMay 22, 2017, 12:36 PM UTC

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

By Nasdaq OMXMay 22, 2017, 12:36 PM UTC

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

By Nasdaq OMXMay 22, 2017, 12:36 PM UTC

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

By Nasdaq OMXMay 22, 2017, 12:36 PM UTC

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

By Nasdaq OMXMay 22, 2017, 12:36 PM UTC

Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy

By Nasdaq OMXJan 3, 2017, 9:53 PM UTC